MTOR and melanoma: Considering that the PI3K/AKT/mTOR pathway may serve as an alternative signaling cascade to the MAPK pathway, contributing to melanoma resistance to MAPK pathway inhibitors such as binimetinib, metformin may potentially mitigate primary cellular resistance to these inhibitors and also suppress the emergence of acquired resistance [34].